• Deal Opens Pathway for Analyte Development
  • Alastair Smith

News & Views

Deal Opens Pathway for Analyte Development

Mar 18 2021

Cancer therapies and diagnostics developer Avacta Group plc has signed an agreement with Biokit, a Werfen Company, to incorporate its Affimer reagents into an in-vitro diagnostic (IVD) product for detection of a key analyte of interest.

Under the licence, Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners, an in-vitro diagnostic (IVD) immunoassay for this analyte. Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.

Details of the agreement were not disclosed.

Dr Marta Palicio, Innovation Director of Biokit commented: "Biokit is very pleased to have reached this agreement with Avacta. The agreement will increase the competitiveness of our customised assay offering for our partners. Avacta’s technology also enables us to innovate our assays with new reagents like Affimer reagents, an alternative to antibodies. We can now move onto the next stage of development, incorporation of this technology into new products. We hope this is the first of many assays containing Affimer reagents which will be developed by Avacta.”

Digital Edition

Lab Asia 30.2 - April 2023

April 2023

In This Edition Chromatography Articles - On-Column Sample Focussing: a Personal Perspective Mass Spectrometry & Spectroscopy Articles - Multi-scale, multi-modal and operando imaging wi...

View all digital editions


Lab & Test Asia

Jun 14 2023 Bangkok, Thailand

HPLC 2023

Jun 18 2023 Dusseldorf, Germany

CPhI & P-MEC China 2023

Jun 19 2023 Shanghai, China

IFPAC 2023

Jul 04 2023 Bethesda, MA, USA


Jul 04 2023 Cardiff, UK

View all events